Ivermectin shows 'antiviral effect' against Covid-19, Japanese company says

  • 📰 asiaonecom
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 59%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

TOKYO - Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday (Jan 31) said that anti-parasite drug ivermectin showed an 'antiviral effect' against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for Covid-19, did not provide further details. Clinical trials...

TOKYO - Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.

Clinical trials are ongoing, but promotion of ivermectin as a Covid-19 treatment has generated controversy. The use of ivermectin to treat Covid-19 is currently being investigated in a UK trial run by the University of Oxford. The researchers said on Monday that it was still under way and they did not want to comment further until they have results to report.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 10. in NG
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ivermectin shows 'antiviral effect' against Covid-19, Japanese company saysstraits_times IVERMECTIN - Anti-Viral, Anti-Cancer, etc. So many Benefits. Yet we are being denied the chance. Is it Fair? And its Very affordable. No wonder Big Companies hate it and say many bad things. What a world.
Source: STForeignDesk - 🏆 4. / 71 Read more »